Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00328172
Status:
COMPLETED
Last Update Posted:
2014-03-14
First Post:
2006-05-18
Brief Title:
Efficacy and Safety of 3 Doses of BI1356 Linagliptin in Type 2 Diabetes Patients
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Organization Data
Organization:
Boehringer Ingelheim
Class:
INDUSTRY
Study ID:
12185
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Boehringer Ingelheim
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Boehringer Ingelheim Study Chair
Old Organization:
Boehringer Ingelheim